Last reviewed · How we verify
Pentalong
Pentalong is a Small molecule drug developed by Jena University Hospital. It is currently in Phase 3 development. Also known as: Pentaeritrithyl tetranitrate, Pentalong® 50 mg.
Pentalong is a small molecule that activates soluble guanylate cyclase, a molecular target involved in various physiological processes. It has been studied in clinical trials for conditions such as type 2 diabetes, high-risk pregnancy, and intrauterine growth restriction.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Pentalong |
|---|---|
| Also known as | Pentaeritrithyl tetranitrate, Pentalong® 50 mg |
| Sponsor | Jena University Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Pentaerithrityl Tetranitrate (PETN) for Secondary Prevention of Intrauterine Growth Restriction (PHASE3)
- Impact of the NO-donor Pentaerythrithyltetrantrate on Perinatal Outcome in High-risk Pregnancies (PHASE1, PHASE2)
- Contraction (Exercise) Mediated Glucose Uptake as a Therapeutic Target in Type 2 Diabetes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pentalong CI brief — competitive landscape report
- Pentalong updates RSS · CI watch RSS
- Jena University Hospital portfolio CI
Frequently asked questions about Pentalong
What is Pentalong?
Who makes Pentalong?
Is Pentalong also known as anything else?
What development phase is Pentalong in?
Related
- Manufacturer: Jena University Hospital — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Pentaeritrithyl tetranitrate, Pentalong® 50 mg
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing